Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris NV's stock outlook is positively influenced by the increase in the global peak sales estimate for its drug deucrictibant to $1.65 billion by 2037, reflecting growing confidence in its market potential. The consistent positive clinical trial data, where 100% of participants reported "well-controlled HAE" status and improvements in health-related quality of life, suggests a strong therapeutic benefit that aligns well with patient needs in a market with limited approved therapies. Furthermore, robust efficacy demonstrated across multiple studies, including rapid onset of symptom relief and durability of response, positions deucrictibant favorably as a potential best-in-class therapy for the treatment and prevention of HAE attacks.

Pharvaris NV faces significant challenges due to the inadequately de-risked nature of bradykinin B2 receptor antagonism in the chronic prophylaxis setting, which raises concerns about the efficacy and safety of its lead candidate, deucrictibant. Additionally, the market for hereditary angioedema (HAE) treatments is highly competitive, dominated by established therapies and segment leaders, which could hinder the market penetration of Pharvaris's product. Furthermore, the anticipated approval of multiple subcutaneous therapies in the coming years poses a risk to Pharvaris’s market share and could limit the uptake of deucrictibant among patients.